Shin Nippon Biomedical Laboratories, Ltd.

Tokyo Stock Exchange 2395.T

Shin Nippon Biomedical Laboratories, Ltd. Interest Coverage Ratio for the year ending March 31, 2024: 51.25

Shin Nippon Biomedical Laboratories, Ltd. Interest Coverage Ratio is 51.25 for the year ending March 31, 2024, a -18.70% change year over year. Interest coverage ratio assesses earnings' ability to cover interest expenses; higher ratios signal lower risk.
  • Shin Nippon Biomedical Laboratories, Ltd. Interest Coverage Ratio for the year ending March 31, 2023 was 63.05, a -3.91% change year over year.
  • Shin Nippon Biomedical Laboratories, Ltd. Interest Coverage Ratio for the year ending March 31, 2022 was 65.62, a 178.18% change year over year.
  • Shin Nippon Biomedical Laboratories, Ltd. Interest Coverage Ratio for the year ending March 31, 2021 was 23.59, a 68.10% change year over year.
  • Shin Nippon Biomedical Laboratories, Ltd. Interest Coverage Ratio for the year ending March 31, 2020 was 14.03, a 161.34% change year over year.
Key data
Date Interest Coverage Ratio Debt to Equity Ratio Interest Expense To Sales Inventory Turnover Ratio
Market news
Loading...
Tokyo Stock Exchange: 2395.T

Shin Nippon Biomedical Laboratories, Ltd.

CEO Dr. Ryoichi Nagata F.F.P.M., M.D., Ph.D.
IPO Date March 8, 2004
Location Japan
Headquarters St. Luke’s Tower
Employees 1,451
Sector Health Care
Industries
Description

Shin Nippon Biomedical Laboratories, Ltd., a contract research organization, provides drug discovery and development services in Japan and internationally. It offers pre-clinical laboratory services, such as good laboratory practice inspections; general and specific toxicity studies; pathological examinations; PK/PD of biopharmaceuticals, immunotoxicity tests, and antibody production; reproductive and developmental toxicity studies; pharmacology and pharmacological efficacy studies; and imaging services. The company also engages in the establishment and validation of analytical methods, analysis of biological samples, and calculation of pharmacokinetic parameters; and provides absorption, distribution, metabolism, and excretion studies using radioisotope-labeled compounds. In addition, it provides site management organization services for clinical trials; clinical contract research organization services; and translational research services, including research and development of nasal delivery systems, nucleic acid adjuvants, and regenerative medicines. The company was founded in 1957 and is headquartered in Tokyo, Japan.

Similar companies

4974.T

Takara Bio Inc.

USD 6.28

-0.78%

4005.T

Sumitomo Chemical Company, Limited

USD 2.11

-1.13%

4507.T

Shionogi & Co., Ltd.

USD 14.22

-0.40%

6869.T

Sysmex Corporation

USD 18.62

0.90%

StockViz Staff

January 15, 2025

Any question? Send us an email